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Tropomyosin-related	kinase	receptor	C	(TrkC)	is	a	neurotrophin	receptor	with	tyrosine	kinase	activity	that	
was	expected	to	be	oncogenic.	However,	it	has	several	characteristics	of	a	tumor	suppressor:	its	expression	
in	tumors	has	often	been	associated	with	good	prognosis;	and	it	was	recently	demonstrated	to	be	a	depen-
dence	receptor,	transducing	different	positive	signals	in	the	presence	of	ligand	but	inducing	apoptosis	in	the	
absence	of	ligand.	Here	we	show	that	the	TrkC	ligand	neurotrophin-3	(NT-3)	is	upregulated	in	a	large	frac-
tion	of	aggressive	human	neuroblastomas	(NBs)	and	that	it	blocks	TrkC-induced	apoptosis	of	human	NB	
cell	lines,	consistent	with	the	idea	that	TrkC	is	a	dependence	receptor.	Functionally,	both	siRNA	knockdown	
of	NT-3	expression	and	incubation	with	a	TrkC-specific	blocking	antibody	triggered	apoptosis	in	human	NB	
cell	lines.	Importantly,	disruption	of	the	NT-3	autocrine	loop	in	malignant	human	neuroblasts	triggered	in	
vitro	NB	cell	death	and	inhibited	tumor	growth	and	metastasis	in	both	a	chick	and	a	mouse	xenograft	model.	
Thus,	we	believe	that	our	data	suggest	that	NT-3/TrkC	disruption	is	a	putative	alternative	targeted	therapeu-
tic	strategy	for	the	treatment	of	NB.
Introduction
According to the classic neurotrophic theory, neuronal survival 
is dependent on neurotrophic factors, such as neurotrophins (1, 
2). These proteins are crucial to the development of the nervous 
system, especially as they control the massive developmental loss 
of excess neurons that fail to adequately connect to their targets. 
However, over the years, neurotrophins — that include NGF, 
BDNF, neurotrophin-3 (NT-3), and NT-4/5 (2) — and their tropo-
myosin-related kinase receptors — TrkA, TrkB, and TrkC — have 
been shown to play an important role in cancer (reviewed in ref. 3). 
The overall view is that, as is the case with classic tyrosine kinase 
receptors, dysregulation of kinase activities through various mech-
anisms generates survival signals via the PI3K/Akt and Ras/MEK/
MAPK pathways, which in turn promote tumor progression (4).
However, TrkC does not seem to fit this picture: (a) its expres-
sion is a good-prognosis factor in different types of cancer and 
more specifically in melanomas (5), medulloblastomas (6, 7) 
and neuroblastomas (NBs) (8–12); (b) its expression and activa-
tion have been shown to trigger apoptosis in medulloblastoma 
cells (13); and (c) as opposed to TrkA and TrkB, it was recently 
proposed to act as a dependence receptor (14). Such receptors 
are able to initiate 2 completely opposite signaling pathways, 
depending on ligand availability. In the presence of ligand, a pos-
itive differentiation, guidance, or survival signal is transduced. 
In the absence of ligand, however, they induce an active process 
of apoptotic cell death. These dependence receptors also include 
p75ntr, deleted in colorectal cancer (DCC), UNC5H, Patched, and 
neogenin and the RET, EPHA4, and Alk tyrosine kinase receptors 
(15–20). The proapoptotic activity of dependence receptors is 
believed to be important for adequate neuron migration or local-
ization during the development of the nervous system (21–23) 
but also for inhibiting tumor growth.
Along this latter line, this dependence on ligand presence is also 
thought to act as a safeguard mechanism to prevent tumor cells 
from developing in settings of ligand unavailability (reviewed in 
refs. 24, 25). This view is supported by the fact that in mouse gas-
trointestinal tracts, disrupting the proapoptotic signaling of a spe-
cific dependence receptor by overexpressing its ligand (netrin-1) or 
inactivating the receptor itself (UNC5H3) is associated with intesti-
nal tumor progression (26, 27). Thus, a tumor losing a dependence 
receptor’s proapoptotic activity would gain a selective advantage 
for growth. This can be achieved by 3 possible mechanisms: (a) 
loss or decrease of expression of the dependence receptor itself as 
extensively described for DCC (28) and more recently for UNC5H 
(25, 27), (b) inactivation of the death signaling pathway, and (c) 
autocrine production of the ligand. The latter is of great interest 
in terms of potential therapy, as extracellular interference between 
ligand and receptor could drive a tumor cell to apoptosis.
We describe here that a large fraction of aggressive NBs that 
express TrkC has evolved toward a gain of NT-3 expression. NB, 
the most frequent solid tumor in young children, is diagnosed as 
a disseminated (stage 4) disease in more than 50% of cases. NB 
prognosis is highly variable depending on ploidy, pathology, and 
MYCN gene amplification (reviewed in ref. 29). Current treatments 
are often limited and induce deleterious side effects. Therefore, 
new treatments need to be developed that are more tumor specific, 
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and consequently, it is key to identify new targets for drug develop-
ment. We show here that NT-3 expression in NB cells is a selective 
advantage for tumor cell survival and propose the disruption of 
the NT-3/TrkC interaction as a novel anticancer strategy to our 
knowledge in NBs with high NT-3 levels.
Results
We focused on stage 4 NBs, with a specific interest in comparing 
the expression levels of NT-3 and its receptor TrkC. We first ana-
lyzed the expression of NT-3 and TrkC using quantitative RT-PCR 
(Q-RT-PCR) in a panel of 106 stage 4 NB tumors. A substantial 
fraction of stage 4 NBs displayed high NT-3 levels (Figure 1A and 
Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI41013DS1). Thirty-eight percent 
of tumors showed at least a 2-fold increase in NT-3 expression 
compared with the median value, and more than 20% of tumors 
displayed a 5-fold increase (Figure 1A). Tumors with high NT-3 
level showed a high NT-3/TrkC ratio, supporting the view of a 
gain of NT-3 expression in tumors (Figure 1A). We then compared 
NT-3 levels to the prognosis within the different subcategories of 
stage 4 NBs — stage 4 either diagnosed before 1 year of age or later 
and stage 4S. No significant differences were observed, suggest-
ing that NT-3 upregulation is a selective gain that occurs inde-
pendently of tumor aggressiveness and dissemination in a large 
fraction of stage 4 NBs. Similar results were obtained on stage 1, 
2, or 3 NBs (Supplemental Figure 1A). Expression of NT-3 was not 
only detected at the mRNA level but also at the protein level by 
immunohistochemistry (Figure 1B).
NT-3 overexpression was seen in 38% of stage 4 NBs but also 
in a fraction of NB cell lines mainly derived from stage 4 NB 
tumor material (Table 1). Four human NB cell lines, i.e., CLB-Ge2, 
CLB-VolMo, SHEP-CLB, and IMR32, were studied further. All 
4 cell lines express TrkC (data not shown), but CLB-Ge2, CLB-
VolMo, and SHEP-CLB express high levels of NT-3, whereas NT-3 
was barely detected in IMR32 cells both at the messengers level 
(Table 1) and at the protein level (Figure 1C). Interestingly, NT-3 
immunostaining performed on CLB-Ge2 and SHEP-CLB cells, 
in the absence of cell permeabilization, showed a clear membra-
nous staining. This suggests that the high NT-3 content observed 
in aggressive NB is associated with an autocrine expression of 
NT-3 in NB cells. We then started investigating the mechanisms 
allowing NT-3 a high level of expression in these cells. We failed to 
detect Ntf3 gene amplification or enhanced transcriptional activ-
ity of the NT-3 promoter in these cells (data not shown). However, 
we noticed that inhibition of methyltransferases with the inhibi-
tor 5-aza-2’-deoxycytidine in either CLB-Ge2 or IMR32 cells spe-
Figure 1
NT-3 is expressed in a large fraction of stage 4 NBs. (A) NT-3 expression and NT-3/TrkC ratio measured by Q-RT-PCR on total RNA from tumors 
from a total of 86 stage 4 NB patients. The percentage of tumors expressing NT-3 at more than 2 fold of the value corresponding to the median is 
indicated. NT-3-low, tumors with low levels of NT-3 expression; NT-3-high, tumors with high levels of NT-3 expression. (B) Representative NT-3 
immunohistochemistry on a tumor biopsy and bone marrow dissociated cells from low (left panel) and high (right panel) NT-3–expressing stage 
4 patients, corresponding to the dotted gray arrow and black arrow in A, respectively. (C) Representative NT-3 immunohistochemistry on CLB-
Ge2, SHEP-CLB, CLB-VolMo, and IMR32 cells. CLB-Ge2 and SHEP-CLB NT-3 immunostaining, when an excess of recombinant NT-3 (r-NT-3) 
is added with primary antibody, is also shown. Note that the 4 top panels show immunohistochemistry performed in absence of membrane per-
meabilization (w/o), while the immunohistochemistry shown in 2 bottom panels was performed after cell permeabilization with Triton X-100 (w). 
(B and C) Insets depict control without primary antibody. Original magnification, ×32.
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cifically restored NT-3 expression in IMR32 cells (Supplemental 
Figure 1B). Together with the general hypomethylation associated 
with cancer, this observation suggests that NT-3 high expression is 
associated with inhibition of NT-3 promoter methylation.
To investigate whether the NT-3 autocrine expression observed 
in CLB-Ge2, CLB-VolMo, and SHEP-CLB cells provides a selective 
advantage for tumor cell survival, as would be expected from the 
dependence receptor paradigm, cell death was analyzed in response 
to the disruption of this autocrine loop. As a first approach, NT-3 
was downregulated by RNA interference. In this approach, we used 
either a mix of 3 siRNA sequences (siRNA NT-3) or 2 of them inde-
pendently (siRNA NT-3-a and siRNA NT-3-b). Efficacy of NT-3 
siRNAs tested was evaluated at the Ntf3 mRNA level by Q-RT-PCR 
(Supplemental Figure 2, A and B) and at the NT-3 protein level 
by immunohistochemistry (Figure 2A) or by ELISA performed on 
the conditioning medium (Supplemental Figure 2A). While scram-
bled siRNA failed to affect cell survival in every cell line studied, as 
measured by caspase activity (Figure 2B) or ToxiLight (Figure 2C) 
assays, the transfection of NT-3 siRNAs was associated with CLB-
Ge2, CLB-VolMol, and SHEP-CLB cell death (Figure 2, B and C, 
and Supplemental Figure 2C). In contrast, IMR32 cell survival was 
unaffected after NT-3 siRNA treatment (Figure 2, B and C, and 
Supplemental Figure 2C).
As a second approach, we used a blocking TrkC antibody 
described before (14) to prevent NT-3 from binding to endog-
enous TrkC. As shown in Figure 2, D and E, and Supplemental 
Figure 2D, the addition of anti-TrkC triggered CLB-Ge2 and CLB-
VolMo apoptotic cell death, as measured by caspase-3 activity assay 
(Figure 2D) and TUNEL staining (Figure 2E and Supplemental 
Figure 2D). This effect was specific for NT-3/TrkC inhibition, 
since the anti-TrkC antibody had no effect on IMR32 cells. Similar 
CLB-Ge2 cell death induction was observed when, instead of using 
a blocking TrkC antibody, a recombinant ectodomain of TrkC was 
used to trap NT-3 (Supplemental Figure 2E).
To determine whether the NB cell death associated with inhibi-
tion of the TrkC/NT-3 interaction can be extended to fresh tumors, 
a surgical biopsy from a tumor and the corresponding bone mar-
row was semi-dissociated and further incubated with the anti-
TrkC antibody. This primary tumor and the disseminated neo-
plasia expressed both NT-3 and TrkC (Supplemental Figure 2F), 
and an increased cell death, measured by caspase activation, was 
detected in response to the anti-TrkC antibody (Figure 2F).
There are 2 different paradigms for interpreting cell death 
associated with the interference of the NT-3/TrkC interaction. 
According to the classic neurotrophic view, the observed cell 
death could be a death by “default” that results from the loss 
of survival signals triggered by the NT-3/TrkC interaction — i.e., 
MAPK or PI3K pathways activated through TrkC’s kinase activity. 
The dependence receptor method offers a different perspective, 
more compatible with the fact that TrkC expression is usually a 
good prognosis factor. In this scenario, blocking the interaction 
between NT-3 and TrkC leads to unbound TrkC actively trigger-
ing apoptosis. As a first approach to discriminate between these 
2 possibilities, NB cell death was induced via anti-TrkC anti-
body treatment, after CLB-Ge2/CLB-VolMo transfection with 
a dominant-negative mutant for TrkC. This dominant-negative 
mutant, TrkC-IC D641N, has been shown to specifically inhibit 
the proapoptotic signaling of unbound TrkC, without affecting 
its kinase-dependent signaling (14). Expression of the dominant-
negative mutant fully blocks anti–TrkC-mediated CLB-Ge2 and 
CLB-VolMo cell death (Figure 3A and Supplemental Figure 3, 
A and B). To further support this observation, we assessed the 
extent of cell death associated with NT-3 siRNA in settings of 
downregulation of TrkC by siRNA. As shown in Figure 3, B and 
C, and Supplemental Figure 3, C–E, while downregulation of 
TrkC in all 3 NT-3–expressing cell lines is not associated with cell 
death as would be expected by the classic loss of survival signal-
ing pathways, this downregulation fully blocks cell death induced 
by NT-3 siRNA. This supports further the hypothesis that NT-3 
upregulation observed in CLB-Ge2, CLB-VolMo, and SHEP-CLB 
cells inhibits the proapoptotic signaling triggered by TrkC itself. 
Along this line, addition of the blocking TrkC antibody to CLB-
Ge2 failed to be associated with a decrease in the classic survival 
pathways, as exemplified here by measurement of ERK or Akt 
phosphorylation (Figure 3D). Moreover, TrkC caspase cleavage 
was enhanced by the TrkC blocking antibody (Figure 3E). Indeed, 
as previously described, TrkC and dependence receptors in gen-
eral are cleaved by caspase, and this cleavage is a prerequisite for 
their proapoptotic activity (14, 16). As shown in Figure 3E, while 
a basal level of TrkC cleavage was detected in control conditions, 
addition of the blocking antibody was associated with increased 
TrkC cleavage, a cleavage blocked by addition of the general 
and potent caspase inhibitor, Boc-Asp(Ome) f luoromethyl 
Table 1
NT-3 expression level and NT-3/TrkC ratio in cell lines derived 
from NBs
Cell line NT-3 (10 × 10–3) NT-3/TrkC
Low NT-3 expression  
IGRN91 0.01 0.0007
IMR32 0.02 0.0000
CLB-Es 0.06 0.0002
CLB-BARREC 0.09 0.0007
CLB-BouLT 0.10 0.0017
CLB-Hut 0.13 0.0002
CLB-Ber2 0.15 0.0007
CLB-Ma2 0.15 0.0008
SKNAS 0.18 0.024
CLB-Ber1 0.20 0.0003
CLB-Tra 0.27 0.0016
CLB-Bel 0.28 0.0002
CLB-Re 0.32 0.0010
SHSY 5Y 0.36 0.2887
High NT-3 expression  
CLB-Ma1 0.57 0.01
CLB-Bar 0.62 0.04
CLB-Pe 0.62 0.005
SHEP-CLB 0.74 2.9
CLB-Ga 0.75 0.33
CLB-Sed 1.02 0.006
CLB-Ge1 3.04 0.01
CLB-Ca 5.47 0.02
CLB-Ge2 8.01 0.14
CLB-VolMo 9.04 0.02
NT-3 expression and NT-3/TrkC ratio measured by Q-RT-PCR in a frac-
tion of NB cell lines. HPRT expression was used as an internal control. 
Number of molecules as calculated by 2exp(ΔCp), where ΔCp is TrkC 
or NT-3 Cp minus HPRT Cp. Values obtained were divided by 1,000. 
Bold indicates cell lines further used in this study.
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ketone (BAF). Together, these data demonstrate that NT-3 
upregulation observed in NB cells inhibits the proapoptotic sig-
naling triggered by the dependence receptor TrkC.
We next assessed whether in vivo interference with NT-3/TrkC 
could be used to limit/inhibit NB progression and dissemination. 
A chicken model was developed in which grafts of NB cells in the 
chorioallantoic membrane (CAM) of 10-day-old chick embryos 
recapitulate both tumor growth at a primary site, within the CAM, 
as well as tumor invasion and dissemination at a secondary site, 
metastasis to the lung (ref. 30 and Figure 4A). In a first approach, 
CLB-Ge2 or IMR32 cells were loaded in 10-day-old CAM, and 
embryos were treated on day 11 and day 14 with anti-TrkC or an 
unrelated antibody. Seventeen-day-old chicks were then analyzed 
for primary tumor growth and metastasis to the lung. As shown in 
Figure 4, B and D, treatment with the anti-TrkC antibody signifi-
cantly reduced primary tumor size, specifically in CLB-Ge2–grafted 
CAM, while an unrelated isotopic antibody had no effect. This size 
reduction was associated with increased tumor cell apoptosis, as 
shown by an increased TUNEL staining in the tumors treated with 
anti-TrkC (Figure 4C). More importantly, anti-TrkC also reduced 
lung metastasis formation in CLB-Ge2–grafted embryos (but not 
in IMR32-grafted embryos), as shown in Figure 4E.
To more specifically address whether the anticancer effect of the 
TrkC blocking antibody was due to the reengagement of TrkC-
induced apoptosis through NT-3/TrkC interaction inhibition, we 
first analyzed the effect of NT-3 siRNA treatment on primary tumors 
in the chicken model. CLB-Ge2 cells were loaded on a 10-day-old 
CAM. Embryos were treated, through injection in the CAM blood 
vessels, on day 11 and day 14 with a siRNA targeting NT-3 or 
scrambled siRNA. Seventeen-day-old chicks were then analyzed 
for primary tumor growth. As shown in Figure 4F, NT-3 siRNA 
treatment was associated with a significant antitumor effect. Of 
interest, when TrkC siRNA treatment was assessed instead of NT-3 
siRNA, no effect on tumor size was observed, further suggesting 
that the antitumor effect seen with the blocking antibody or with 
NT-3 siRNA is not associated with a “classic” loss of the surviv-
al signals promoted by the tyrosine kinase activity of TrkC. On 
the other hand, we show that a dual treatment with NT-3 siRNA 
and TrkC siRNA reversed the anticancer effect observed in NT-3 
siRNA–treated CAM (Figure 4F). This result thus demonstrates 
that NT-3 inhibition is associated with tumor growth inhibition 
and cell death, because it reengages TrkC-induced apoptosis.
To further provide a proof of concept that NT-3 interference may 
represent a putative alternative therapeutic approach, classic xeno-
Figure 2
Disruption of NT-3 autocrine loop triggers NB cell death. (A) NT-3 immunostaining on the CLB-Ge2 cell line 24 hours after transfection with 
scrambled siRNA (siRNA scr) or with NT-3 siRNA (siRNA NT-3). Insets depict control without primary antibody. Original magnification, ×32. (B 
and C) Cell death induction in CLB-Ge2, CLB-VolMo, SHEP-CLB, and IMR32 cell lines was quantified after transfection with either scrambled 
siRNA or a mix of 3 siRNAs targeting NT-3, using relative caspase-3 activity assay (B) or Toxilight assay (C). (D and E) Cell death induction in 
CLB-Ge2, CLB-VolMo, or IMR32 cell lines was quantified in cells treated with anti-TrkC blocking antibody (α TrkC) or without (control) anti-TrkC 
antibody, using relative caspase-3 activity assay (D) or TUNEL assay (E). For the TUNEL assay, a representative labeling of TUNEL-positive 
cells is shown (top panel, control cells; bottom panel, cells treated with anti-TrkC blocking antibody). Original magnification, ×20. (F) Effect of anti-
TrkC blocking antibody on stage 4 NB. Tumoral cells were directly dissociated from the surgical biopsy and were plated for 24 hours in presence 
(+) or in absence (-) of treatment. (B–F) Data represent mean ± SEM. *P < 0.05, 2-sided Mann-Whitney test, compared with control.
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grafts of NB cells in nude mice were performed. SHEP-CLB were 
xenografted subcutaneously in nude mice. When the engrafted 
tumors reached 100 mm3, mice were treated intraperitoneally 3 time 
a week, either with NT-3 siRNA or with scrambled siRNA as success-
fully performed previously (31, 32). As shown in Figure 5, the growth 
of tumors engrafted in mice treated with NT-3 siRNA was strongly 
reduced compared with the ones engrafted in scrambled siRNA–
treated mice. This tumor growth inhibition was associated with a 
reduction in tumor weight. Together, these data further support the 
antitumor effect associated with NT-3 interference in vivo.
Discussion
We show here that a fraction of NBs show an autocrine production 
of NT-3 associated with an increased NT-3/TrkC ratio. This elevated 
NT-3/TrkC ratio likely confers a selective advantage acquired by the 
cancer cells in settings of limited/no NT-3. Interestingly, this depen-
dence on NT-3 presence appears specific for TrkC and does not 
involve other Trk receptors (i.e., TrkA or TrkB), as a dominant nega-
tive of TrkC is sufficient to turn down this dependence (Figure 3A). 
Both NT-3 and TrkC have been shown to be expressed in various 
cancers (5, 33–47). However, most of the field has concentrated its 
attention on the expression of TrkC, considered as a favorable out-
come factor in NB and medulloblastoma (6–8, 10–12). All these 
studies view NT-3 as an accessory compound that complements 
TrkC autoactivation and induces proliferation through TrkC 
kinase–dependent signaling. Along this line, NT-3 was shown to 
induce survival and differentiation of primary cultures derived 
from NB (48) and further to activate heparanase activity through 
TrkC and be involved in invasion during metastasis (49–51).
Here, we show that autocrine NT-3 expression is a mechanism 
developed by a large fraction of tumor cells to bypass TrkC-
induced cell death that would occur in regions of limited NT-3 
concentrations. This selective advantage is, however, only 1 of 3 
possible means a tumor can use to inactivate TrkC-induced apop-
tosis, the 2 others being either a loss of TrkC expression or an 
inactivation of the downstream proapoptotic signaling. Along this 
later line, IMR32 cells are NT-3–negative cells and undergo apop-
tosis through forced expression of Bax, a classic cell death inducer. 
Figure 3
NT-3/TrkC interference promotes TrkC proapoptotic activity. (A) CLB-Ge2 cells were transfected with either empty vector or with a plasmid 
encoding the dominant-negative TrkC-IC D641N and treated for 24 hours with or without anti-TrkC blocking antibody Cell death was monitored 
by TUNEL labeling of cells plated on slides. The control panel shows TrkC-IC D641N by Western blots using anti-TrkC antibody (bottom panel). 
Representative images are shown. Original magnification, ×20. (B) The efficacy of TrkC siRNA was evaluated by Western blot on nonexpress-
ing TrkC 13.S.24 olfactive neuroblasts. Cells were transfected either with empty vector or with uncleavable TrkC D945N D641N double mutant 
that does not trigger apoptosis, and with scrambled siRNA or TrkC siRNA (siRNA TrkC). (C) Cell death induction in the CLB-Ge2 cell line was 
quantified after transfection with either scrambled siRNA (siScr), TrkC siRNA (siTrkC), NT-3 siRNA (siNT-3), or a mix of TrkC and NT-3 siRNA, 
using relative caspase-3 activity assay. (D) Phospho-Akt and phospho-Erk levels of CLB-Ge2 cells were monitored by Western blot after 16 
hours of treatment with 2 μg/ml anti-TrkC blocking antibody 20 nM Ly29402, 100 nM U0126, or 100 ng/ml NT-3, in absence of serum. (E) Detec-
tion of TrkC cleavage band (20 kDa, indicated by the arrow) by Western blot, using an anti-TrkC antibody on cells treated (or not) with anti-TrkC 
blocking antibody, with or without the general caspase inhibitor BAF. (A and C) Data represent mean ± SEM. *P < 0.05, 2-sided Mann-Whitney 
test, compared with control.
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Nevertheless, they fail to die after TrkC overexpression (Supple-
mental Figure 4), thus suggesting that in IMR32 cells, the loss of 
TrkC proapoptotic signaling has been selected. As a consequence, 
NT-3 high expression constitutes a new marker for NB patients 
that could putatively respond to a treatment based on cell death 
induction via disruption of the NT-3/TrkC interaction. One may 
wonder, what are the mechanisms leading to NT-3 upregulation. 
Our preliminary results suggest that NT-3 expression in cancer 
cells may be regulated by epigenetic mechanisms, but further work 
will be needed to address this important point.
The in vitro cell death effect and the in vivo antitumor effect of 
NT-3 interference on NT-3–expressing tumor cells support the view 
that NT-3 is an exciting target for drug development. So far, the 
data obtained are still limited in term of the number of models 
tested and also on the amplitude of the anticancer effect observed 
(Figures 4 and 5). This, however, could be explained by the fact that 
the tools used here (siRNA or polyclonal antibody) were proof-of-
concept tools and definitely not drug candidate tools. Drug devel-
opment has now to be explored. However, our data calls for a larger 
screen of cancers that could be responsive to such a therapeutic 
approach. Indeed, the therapeutic strategy presented here is funda-
mentally different from the now classic strategies for cancer therapy 
based on inhibitors of tyrosine kinase activity. In our view, inhibit-
ing the kinase activity-dependent survival signals triggered by TrkC 
should only have poor tumor death effect, i.e., cytostatic, if the drug 
developed does not also target the activation of the proapoptotic 
activity of TrkC. We propose here that a treatment based on inhibi-
tion of the interaction between NT-3 and its dependence receptor 
TrkC, by blocking either NT-3 or TrkC, could potentially provide 
benefit, as a first line treatment or in combination with standard 
chemotherapy, to the large fraction of the patients suffering from 
aggressive NB and possibly other cancers with high NT-3 levels.
Figure 4
Blocking NT-3/TrkC inhibits NB growth and dissemination. (A) Schematic representation of the experimental chick model. IMR32 or CLB-Ge2 
cells were grafted in CAM at day 10, and anti-TrkC blocking antibody or an isotypic antibody (control antibody) was added on day 11 and day 14. 
Tumors and lungs were harvested on day 17. (B–D) Effect of anti-TrkC blocking antibody on primary tumor growth and apoptosis. (B) Represen-
tative images of CLB-Ge2 primary tumors formed on nontreated CAM or CAM treated either with an isotypic antibody (control antibody) or with 
anti-TrkC blocking antibody. Scale bar: 2 μm. (C) Representative images of TUNEL-positive cells in the respective primary tumors described in 
B. Scale bar: 100 μm. (D) Quantitative analysis showing the primary tumor size relative to nontreated tumors. (E) Effect of anti-TrkC blocking 
antibody on lung metastasis. The percentage of embryos with lungs invaded by IMR32 or CLB-Ge2 cells after 2 intratumoral injections (day 11 
and day 14) of either anti-TrkC blocking antibody, an isotypic antibody, or nontreated. (F) Same as for D except that NT-3, TrkC, scrambled, or 
NT-3 and TrkC siRNA were injected on a chorioallantoic vessel. Relative primary tumor size is presented. (D and F) Data represent mean ± SEM. 
*P < 0.05, **P < 0.01, 2-sided Mann-Whitney test, compared with nontreated tumors. (E) **P < 0.01, χ2 test.
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Methods
Human NB and breast tumors samples and biological annotations. After the con-
sent of parents, surgical human NB tumor material was immediately frozen. 
Materials and annotations were obtained from the Biological Resources 
Centers of both national referent institutions for NB treatment, i.e., Centre 
Léon Bérard and Institut Gustave Roussy. Approval of care and use of these 
samples was given by the Biological Resources Center Ethical and Steering 
committees of Centre Léon Bérard and Institut Gustave Roussy.
Cell lines, transfection procedure, and reagents. Human NB cell lines were from 
the tumor banks at Centre Léon Bérard and at Institut Gustave Roussy. 
CLB-Ge2, CLB-VolMo, SHEP-CLB, and IMR32 cell lines were cultured in 
RPMI 1640 Glutamax medium (Gibco) containing 10% fetal bovine serum. 
Cells were transfected using Lipofectamine 2000 Reagent (Invitrogen). 
Tumor biopsies and bone marrow cells were immediately dissociated and 
cultured on RPMI 1640 Glutamax medium (Gibco) containing 10% fetal 
bovine serum. Olfactory neuroblasts 13.S.24 were cultured and transfected 
as previously described (14). Anti-TrkC blocking antibody was obtained 
from R&D Systems (catalog AF1404). The recombinant TrkC/Fc chimera 
corresponding to the extracellular domain of human TrkC (Fc-TrkC-EC) 
was obtained from R&D Systems (catalog 373-TC). BAF caspase inhibi-
tor (20 mM) and 5-aza-2’-deoxycytidine methylation inhibitor (5 μM) were 
from Sigma-Aldrich (A3656).
Plasmid constructs and siRNA. The TrkC dominant-negative mutant TrkC-IC 
D641N and uncleavable TrkC D495N/D641N were described before (14). 
Scrambled siRNA (catalog sc-37007) and NT-3 siRNA (catalog sc-42125, 
sc-42125-A, and sc-42125-B) were obtained from Santa Cruz Biotechnol-
ogy Inc. TrkC siRNA was from Sigma-Aldrich (SASI_Hs01_00192145 and 
SASI_Hs01_00192145_AS).
Cell death assays. 2 × 105 cells were grown in serum-poor medium and 
were treated (or not) with 2 μg/ml anti-TrkC antibody (catalog AF1404, 
R&D Systems) and 2 μg/ml Fc-TrkC-EC (catalog 373-TC; R&D Systems) 
or transfected with siRNA or TrkC constructs, using Lipofectamine 2000 
(Invitrogen) for CLB-Ge2, CLB-VolMo, and SHEP-CLB cells or Lipo-
fectamine Plus for IMR32 cells (Invitrogen). Cell death was analyzed 
24 hours after treatment/transfection either by trypan blue exclusion as 
described previously (15) or with ToxiLight Bio Assay kit (Lonza). Apopto-
sis was monitored by measuring caspase-3 activity as described previously 
(15), using the ApoAlert CPP32 Kit from Clontech (USA). For detection 
of DNA fragmentation, CLB-Ge2 cells were grown in poly-l-lysine–coat-
ed slides and fixed with 4% PFA 24 hours after treatment/transfection. 
IMR32- and CLB-VolMo–transfected cells were cytospun before PFA fixa-
tion. TUNEL was performed with 300 U/ml TUNEL enzyme and 6 μM 
biotinylated dUTP (Roche Diagnostics), as described previously (52).
Q-RT-PCR. To assay NT-3 and TrkC expression in NB samples, total RNA 
was extracted from histologically qualified tumor biopsies (>60% imma-
ture neuroblasts), using the Nucleospin RNAII Kit (Macherey-Nagel), and 
200 ng were reverse transcribed using 1 U SuperScript II Reverse Transcrip-
tase (Invitrogen), 1 U RNAse inhibitor (Roche Applied Science), and 250 ng 
random hexamer (Roche Applied Science). Total RNA was extracted from 
human cell lines using the Nucleospin RNAII Kit (Macherey-Nagel), and 
1 μg was reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-
Rad). Real-time Q-RT-PCR was performed on a LightCycler 2.0 apparatus 
(Roche), using the Light Cycler FastStart DNA Master SYBER Green I Kit 
(Roche). Q-RT-PCR was performed using the following primers: TrkC, for-
ward 5′-AGCTCAACAGCCAGAACCTC-3′ and reverse 5′-AACAGCGTT-
GTCACCCTCTC-3′; NT-3, forward 5′-GAAACGCGATGTAAGGAAGC-
3′ and reverse 5′-CCAGCCCACGAGTTTATTGT-3′. The ubiquitously 
expressed human HPRT gene, showing the least variable expression in NB, 
was used as an internal control, using the following primers: forward 
5′-TGACACTGGCAAAACAATGCA-3′ and reverse 5′-GGTCCTTTTCAC-
CAGCAAGCT-3′. For all 3 couples of primers, polymerase was activated at 
95°C for 10 minutes, followed by 35 cycles at 95°C for 10 seconds, 60°C 
for 10 seconds, and 72°C for 5 seconds.
Immunohistochemistry and immunoblot. 8 × 104 cells were cytospun on 
coverslips and fixed in 4% PFA. The slides were then incubated at room 
temperature for 1 hour with an antibody recognizing human NT-3 (1:300; 
Figure 5
Disruption of NT-3 autocrine loop inhibits NB tumor growth. (A) The volume of SHEP-CLB engrafted tumors was measured during treatment 
with either NT-3 siRNA or scrambled siRNA. Mice were injected intraperitoneally with 3 μg siRNA 3 times per week. Mean tumor volume is indi-
cated. (B) SHEP-CLB tumors were dissected after 18 days of treatment. Final tumor weight and representative pictures are shown. Scale bar: 
2 mm. Data represent mean ± SEM. **P < 0.01, ***P < 0.001, 2-sided Mann-Whitney test, compared with scrambled siRNA–treated mice.
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catalog sc-547, Santa Cruz Biotechnology Inc.). After rinsing in PBS, the 
slides were incubated with an Alexa Fluor 488–conjugated donkey anti-
rabbit antibody (Molecular Probes). Nuclei were visualized with Hoechst 
staining (Sigma-Aldrich).
Expression of TrkC constructs and endogenous TrkC cleavage were 
monitored by Western blot with anti-Trk antibody (catalog sc-11; Santa 
Cruz Biotechnology Inc.), and an anti α-actin (13E5; Cell Signaling Tech-
nology) was used as loading control as previously described (14).
Phospho-Akt and phospho-Erk levels of CLB-Ge2 cells were measured 
by Western blot with anti–phospho-Akt (4058, Cell Signaling Technology) 
and phospho-Erk1 and Erk2 (E7028, Sigma-Aldrich) after 16 hours of 
culture on serum-free medium with 2 μg/ml anti-TrkC antibody (catalog 
AF1404, R&D Systems), 20 nM Ly29402 (Sigma-Aldrich), 100 nM U0126 
(Sigma-Aldrich), or 100 ng/ml NT-3 (Abcys).
ELISA determination of NT-3 level. For NT-3 determination in cell culture 
supernatants, 13.S.24 cells were transfected with a human NT-3 con-
struct and scrambled siRNA or NT-3 siRNA. Supernatants were collected 
24 hours later. A white 96-well plate (CORNING) was coated with a mono-
clonal human NT-3 antibody (MAB267, R&D systems), blocked with 
bovine serum albumin, and incubated with the samples, followed by detec-
tion of NT-3 by using a biotinylated anti-human NT-3 antibody (BAF267, 
R&D systems), a streptavidin-peroxidase polymer (S2438, Sigma-Aldrich), 
and a chemiluminescent substrate (Pierce ECL Western Blotting Substrate). 
The luminescence was read on a Tecan Infinite P500 luminometer. Human 
recombinant NT-3 (P450-03, Abcys) was used as standard in the ELISA.
Chicken model for NB progression and dissemination. 107 NB cells suspended 
in 40 μl complete medium were seeded on 10-day-old (day 10) chick CAM. 
2 μg anti-TrkC antibody or an isotypic unrelated antibody (catalog sc-1290, 
Santa Cruz Biotechnology Inc.) were injected in the tumor on day 11 and 
day 14. For siRNA treatment, 3 μg of scrambled, TrkC, or NT-3 siRNA 
were injected in a chorioallantoic vessel on days 11 and 14. On day 17, 
tumors were resected, and area was measured with AxioVision Release 4.6 
software (Zeiss). To monitor apoptosis on primary tumors, they were fixed 
on 4% PFA, cryoprotected by overnight treatment with 30% sucrose, and 
embedded in Cryomount (Histolab). TUNEL staining was performed on 
tumor cryostat sections (Roche Diagnostics), and nuclei were stained with 
Hoechst. To assess metastasis, lungs were harvested from the tumor-bear-
ing embryos and genomic DNA was extracted with the NucleoSpin Tis-
sue Kit (Macherey Nagel). Metastasis was quantified by Q-RT-PCR detec-
tion of the human Alu sequence, using the following primers: forward 
5′-ACGCCTGTAATCCCAGCACTT-3′ and reverse 5′-TCGCCCAGGCT-
GGAGTGCA-3′. Chick GAPDH-specific primers were used as controls, 
using the following primers: forward 5′-GAGGAAAGGTCGCCTGGTG-
GATCG-3′ and reverse 5′-GGTGAGGACAAGCAGTGAGGAACG-3′. For 
both couples of primers, amplification was assessed at 95°C for 2 minutes, 
followed by 30 cycles at 95°C for 30 seconds, 63°C for 30 seconds, and 
72°C for 30 seconds. Genomic DNA extracted from lungs of noninocu-
lated chick embryos was used to determine the threshold.
Xenograft of human NB cells in nude mice. Five-week-old (20–22 g body weight) 
female athymic nu/nu mice were obtained from Charles River. Approval of 
care and use of mice was given by ethical committees of Centre Léon Bérard 
and by the French Ministry of Research. The mice were housed in steril-
ized filter-topped cages and maintained in a pathogen-free animal facility. 
SHEP-CLB cells were implanted by subcutaneous injection of 5 × 106 cells 
in 200 μl PBS into the flank of the mice to make 1 tumor per mouse. When 
tumors reached a volume of 100 mm3, approximately 11 days after injec-
tion, 3 μg of either scrambled or NT-3 siRNA, diluted in 300 μl of PBS, were 
injected intraperitoneally 3 times per week for 18 days. Tumor sizes were 
measured with a caliper. The tumor volume was calculated with the follow-
ing formula: v = 0.5 (l × w2), where v is volume, l is length, and w is width.
Statistics. Data presented are representative of at least 3 independent 
experiments. Unless otherwise indicated, data are mean ± SEM. Statistical 
significance of differences between means was assessed by a Mann-Whitney 
test for paired values. Categorical data was analyzed with the χ2 test. All 
statistical tests were 2-sided. P values of less than 0.05 were considered to 
be statistically significant.
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